Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

31.30 USD +2.50 (+8.68%)
Official Closing Price Updated: 4:32 PM EST, Jan 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Esperion Theraptc

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
From GlobeNewswire News Releases
Esperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland
From GlobeNewswire News Releases
ESPERION Appoints Sheldon Koenig as Chief Operating Officer
From GlobeNewswire News Releases
NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study Su
From GlobeNewswire News Releases
Esperion Announces Pricing of Offering of $250.0 Million of Convertible Senior Subordinated Notes
From GlobeNewswire News Releases
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
From GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
From GlobeNewswire News Releases
Esperion to Participate in Three Upcoming Virtual Investor Conferences
From GlobeNewswire News Releases
Esperion to Report Third Quarter 2020 Financial Results November 2, 2020
From GlobeNewswire News Releases
NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia
- NEXLETOL® exhibited a 22% mean reduction in LDL-C levels in patients with Heterozygous Familial Hypercholesterolemia at week-12 - 
From GlobeNewswire News Releases
Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
From GlobeNewswire News Releases
Esperion to Participate in Two Upcoming Virtual Investor Conferences
From GlobeNewswire News Releases
Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020
From GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
From GlobeNewswire News Releases
Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
From GlobeNewswire News Releases
Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bemp
From GlobeNewswire News Releases
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement
From GlobeNewswire News Releases
Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Session
From GlobeNewswire News Releases
Esperion Confirms NEXLETOL™ (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER
From GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
From GlobeNewswire News Releases
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
From GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
From GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
From GlobeNewswire News Releases
Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
From GlobeNewswire News Releases
Esperion to Report First Quarter 2020 Financial Results May 6, 2020
From GlobeNewswire News Releases
Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.